{"id":8073,"date":"2025-07-24T14:03:12","date_gmt":"2025-07-24T11:03:12","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8073"},"modified":"2025-07-24T14:03:12","modified_gmt":"2025-07-24T11:03:12","slug":"integrated-criteria-for-cardiology-centers-of-excellence-developed-from-key-international-cardiology-guidelines-and-expert-consensus","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/integrated-criteria-for-cardiology-centers-of-excellence-developed-from-key-international-cardiology-guidelines-and-expert-consensus\/","title":{"rendered":"Integrated Criteria for Cardiology Centers of Excellence Developed from key international cardiology guidelines and expert consensus."},"content":{"rendered":"
Integrated Criteria for Cardiology Centers of Excellence<\/div>\n
<\/div>\n
Developed from key international cardiology guidelines and expert consensus.<\/div>\n
<\/div>\n
Source:\u00a0 Integrated Criteria for Cardiology Centers of Excellence<\/div>\n
<\/div>\n
In reference to these standards, please find below a concise summary of the internationally recognized criteria for establishing and accrediting Centers of Excellence in cardiology. This framework was developed from key international cardiology guidelines and trusted expert consensus:<\/div>\n
1. Heart Failure (HF)<\/span><\/div>\n
2. Heart Transplantation<\/span><\/div>\n
3. Atrial Fibrillation (AF)<\/span><\/div>\n
4. Ventricular Arrhythmias (VT\/VF)<\/span><\/div>\n
\u00a0 \u00a0 \u00a0 5.\u00a0 Hypertrophic Cardiomyopathy (HOCM)<\/div>\n
These standards are compiled based on evidence-based guidelines and frameworks from leading cardiology organizations including the Heart Failure Society of America (HFSA), American College of Cardiology (ACC), American Heart Association (AHA), Heart Rhythm Society (HRS), and the European Society of Cardiology (ESC).<\/div>\n
<\/div>\n
1. Heart Failure Center of Excellence (HF CoE)<\/div>\n
<\/div>\n
Definition:<\/div>\n
A Heart Failure Center of Excellence is a multidisciplinary, high-quality program designed to provide comprehensive care for patients across all stages of heart failure (HF), from diagnosis through advanced therapies and palliative support.<\/div>\n
<\/div>\n
Core Criteria:<\/div>\n
<\/div>\n
A. Multidisciplinary HF Team<\/div>\n
\u2022 Advanced HF cardiologists<\/span><\/div>\n
\u2022 Heart failure nurse specialists<\/span><\/div>\n
\u2022 Clinical pharmacists<\/span><\/div>\n
\u2022 Nutritionists<\/span><\/div>\n
\u2022 Psychologists or counselors<\/span><\/div>\n
\u2022 Social workers<\/span><\/div>\n
\u2022 Physical therapists<\/span><\/div>\n
<\/div>\n
B. Diagnostic Capabilities<\/div>\n
\u2022 Echocardiography (including strain imaging)<\/span><\/div>\n
\u2022 Cardiac MRI<\/span><\/div>\n
\u2022 Right heart catheterization<\/span><\/div>\n
\u2022 Cardiac biomarkers (BNP, NT-proBNP)<\/span><\/div>\n
\u2022 Genetic counseling and testing when indicated<\/span><\/div>\n
<\/div>\n
C. Structured Clinical Pathways<\/div>\n
\u2022 ACC\/AHA\/HFSA or ESC-aligned protocols<\/span><\/div>\n
\u2022 Management by HF category: HFrEF, HFpEF, HFmrEF<\/span><\/div>\n
\u2022 Optimization of guideline-directed medical therapy (GDMT)<\/span><\/div>\n
\u2022 Transition of care planning and readmission prevention<\/span><\/div>\n
<\/div>\n
D. Advanced Therapeutic Access<\/div>\n
\u2022 CRT, ICD<\/span><\/div>\n
\u2022 LVAD programs<\/span><\/div>\n
\u2022 Referral or integration with heart transplant services<\/span><\/div>\n
\u2022 Palliative care integration<\/span><\/div>\n
<\/div>\n
E. Data & Quality Monitoring<\/div>\n
\u2022 Participation in national or regional HF registries (e.g., GWTG-HF, ESC-HF Registry)<\/span><\/div>\n
\u2022 30-day readmission and mortality tracking<\/span><\/div>\n
\u2022 Risk stratification tools: Seattle HF Model, MAGGIC<\/span><\/div>\n
<\/div>\n
F. Patient Education and Engagement<\/div>\n
\u2022 Structured education programs<\/span><\/div>\n
\u2022 Self-care tools and telemonitoring<\/span><\/div>\n
\u2022 Shared decision-making models<\/span><\/div>\n
<\/div>\n
G. Research and Innovation<\/div>\n
\u2022 Clinical trials participation<\/span><\/div>\n
\u2022 Quality improvement projects<\/span><\/div>\n
\u2022 HF training and fellowships<\/span><\/div>\n
<\/div>\n
References:<\/div>\n
https:\/\/www.hfsa.org<\/div>\n
https:\/\/www.acc.org\/latest-in-cardiology\/ten-points-to-remember\/2022\/12\/14\/14\/59\/2022-aha-acc-hf-guideline<\/div>\n
https:\/\/www.escardio.org\/Guidelines\/Clinical-Practice-Guidelines\/Heart-Failure<\/div>\n
<\/div>\n
2. Heart Transplant Center of Excellence<\/div>\n
<\/div>\n
Definition:<\/div>\n
To establish and accredit a Heart Transplant Center of Excellence, the following key criteria\u2014adopted from CMS, UNOS, and OPTN\u2014must be met.<\/div>\n
<\/div>\n
Core Criteria:<\/div>\n
1. Minimum Annual Case Volume<\/span><\/div>\n
Perform at least 10\u201312 heart transplants annually to ensure institutional experience and procedural proficiency.<\/div>\n
2. Survival Rates<\/span><\/div>\n
Maintain \u226585% 1-year survival rate and high 3-year survival outcomes.<\/div>\n
3. Multidisciplinary Transplant Team<\/span><\/div>\n
Includes transplant surgeons, advanced HF cardiologists, transplant coordinators, anesthesiologists, infectious disease experts, immunologists, psychologists, social workers, dietitians, and rehabilitation specialists.<\/div>\n
4. Comprehensive Pre- and Post-Transplant Support<\/span><\/div>\n
Access to LVAD, immunologic evaluation, psychosocial screening, and lifelong structured outpatient follow-up.<\/div>\n
5. Organ Allocation and Ethical Compliance<\/span><\/div>\n
Strict adherence to national organ allocation policies and transparent, equitable listing procedures.<\/div>\n
6. Data Reporting and Quality Monitoring<\/span><\/div>\n
Submit outcome data (waitlist mortality, readmissions, complications) to CMS\/OPTN registries.<\/div>\n
7. Participation in Registries and Research<\/span><\/div>\n
Engage in transplant research and continuous quality improvement using national transplant databases.<\/div>\n
8. Accreditation and Peer Review<\/span><\/div>\n
Maintain active accreditation and undergo regular performance evaluation via SRTR or CMS.<\/div>\n
9. Patient and Family Education<\/span><\/div>\n
Provide structured transplant education covering lifestyle, medications, rejection signs, and long-term management.<\/div>\n
10. Infrastructure and Facilities<\/span><\/div>\n
Fully equipped ICU, immunology labs, tissue typing, and surgical support.<\/div>\n
<\/div>\n
References:<\/div>\n
https:\/\/optn.transplant.hrsa.gov<\/div>\n
https:\/\/unos.org<\/div>\n
https:\/\/www.cms.gov<\/div>\n
<\/div>\n
3. Atrial Fibrillation Center of Excellence (AF CoE)<\/div>\n
<\/div>\n
Definition:<\/div>\n
A comprehensive center offering full-spectrum care for patients with AF\u2014from early diagnosis to catheter ablation, stroke prevention, and long-term management.<\/div>\n
<\/div>\n
Core Criteria:<\/div>\n
<\/div>\n
A. Specialized AF Team<\/div>\n
\u2022 Cardiac EPs<\/span><\/div>\n
\u2022 AF nurse coordinators<\/span><\/div>\n
\u2022 Stroke team<\/span><\/div>\n
\u2022 Clinical pharmacists<\/span><\/div>\n
\u2022 Imaging specialists (CT\/MRI)<\/span><\/div>\n
\u2022 Anticoagulation service<\/span><\/div>\n
<\/div>\n
B. Integrated Care Pathway<\/div>\n
\u2022 CHA\u2082DS\u2082-VASc and HAS-BLED scoring<\/span><\/div>\n
\u2022 ESC 2020 or AHA\/ACC\/HRS 2019 pathway alignment<\/span><\/div>\n
\u2022 Lifestyle interventions: weight loss, sleep apnea, smoking cessation<\/span><\/div>\n
<\/div>\n
C. Ablation Services<\/div>\n
\u2022 RFA, Cryoballoon, PFA<\/span><\/div>\n
\u2022 Mapping systems (e.g., CARTO, EnSite)<\/span><\/div>\n
\u2022 ICE-guided procedures<\/span><\/div>\n
\u2022 Same-day discharge when appropriate<\/span><\/div>\n
<\/div>\n
D. Stroke Prevention<\/div>\n
\u2022 DOAC\/Warfarin management<\/span><\/div>\n
\u2022 Watchman device or other LAAO interventions<\/span><\/div>\n
<\/div>\n
E. Monitoring and Follow-up<\/div>\n
\u2022 Holter, mobile ECG, loop recorders<\/span><\/div>\n
\u2022 Remote arrhythmia detection and EMR integration<\/span><\/div>\n
<\/div>\n
F. Patient Engagement<\/div>\n
\u2022 Educational resources<\/span><\/div>\n
\u2022 Shared decision-making tools<\/span><\/div>\n
\u2022 Virtual visits and structured telemonitoring<\/span><\/div>\n
<\/div>\n
G. Metrics and Quality Indicators<\/div>\n
\u2022 AF burden reduction<\/span><\/div>\n
\u2022 EHRA score improvement<\/span><\/div>\n
\u2022 Recurrence rate post-ablation<\/span><\/div>\n
\u2022 Anticoagulation adherence<\/span><\/div>\n
<\/div>\n
H. Accreditation and Registry Participation<\/div>\n
\u2022 GWTG-AFIB or national AF registries<\/span><\/div>\n
\u2022 HRS CoE framework compliance<\/span><\/div>\n
<\/div>\n
References:<\/div>\n
https:\/\/www.hrsonline.org\/AFCoE<\/div>\n
https:\/\/www.escardio.org\/Guidelines\/Clinical-Practice-Guidelines\/Atrial-Fibrillation<\/div>\n
https:\/\/www.jacc.org\/doi\/10.1016\/j.jacc.2019.01.011<\/div>\n
<\/div>\n
4. Ventricular Arrhythmia \/ Tachycardia Center of Excellence (VT\/VF CoE)<\/div>\n
<\/div>\n
Definition:<\/div>\n
A VT\/VF CoE is designed for high-risk patients with life-threatening ventricular arrhythmias. These centers integrate emergency care, ablation, device management, and long-term follow-up.<\/div>\n
<\/div>\n
Core Criteria:<\/div>\n
<\/div>\n
A. Specialized EP Infrastructure<\/div>\n
\u2022 High-volume EP team<\/span><\/div>\n
\u2022 Advanced 3D mapping systems (e.g., CARTO, RHYTHMIA)<\/span><\/div>\n
\u2022 Contact force catheters, ICE, magnetic navigation<\/span><\/div>\n
<\/div>\n
B. Multidisciplinary Team<\/div>\n
\u2022 EPs, heart failure specialists, interventional cardiologists<\/span><\/div>\n
\u2022 ICU physicians, cardiac surgeons<\/span><\/div>\n
<\/div>\n
C. Advanced Procedural Options<\/div>\n
\u2022 Epicardial and scar-related VT ablation<\/span><\/div>\n
\u2022 Management of VT storm and electrical storms<\/span><\/div>\n
\u2022 Sympathetic denervation in select cases<\/span><\/div>\n
<\/div>\n
D. Device Expertise<\/div>\n
\u2022 ICD\/CRT implantation<\/span><\/div>\n
\u2022 Programming for ATP\/shock minimization<\/span><\/div>\n
\u2022 Remote monitoring with arrhythmia alerts<\/span><\/div>\n
<\/div>\n
E. Emergency Systems<\/div>\n
\u2022 24\/7 EP response protocols<\/span><\/div>\n
\u2022 Structured management for sudden cardiac arrest<\/span><\/div>\n
\u2022 Post-resuscitation rehab<\/span><\/div>\n
<\/div>\n
F. Long-Term Management<\/div>\n
\u2022 Standardized follow-up<\/span><\/div>\n
\u2022 Psychosocial support and lifestyle counseling<\/span><\/div>\n
\u2022 Recurrence tracking<\/span><\/div>\n
<\/div>\n
G. Research and Registry Reporting<\/div>\n
\u2022 Inclusion in multicenter VT trials<\/span><\/div>\n
\u2022 Outcomes tracking: acute success, VT-free survival, mortality<\/span><\/div>\n
<\/div>\n
References:<\/div>\n
https:\/\/www.hrsonline.org<\/div>\n
https:\/\/www.escardio.org\/Guidelines\/Clinical-Practice-Guidelines\/Ventricular-Arrhythmias-and-the-Prevention-of-Sudden-Cardiac-Death<\/div>\n
https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2022\/03\/03\/20\/26\/hrs-guidance-on-catheter-ablation-of-ventricular-arrhythmias<\/div>\n
5.\u00a0 Hypertrophic Cardiomyopathy (HOCM) Center of Excellence \u2013 Comprehensive Criteria<\/div>\n
<\/div>\n
Introduction<\/div>\n
<\/div>\n
This document outlines the internationally recognized criteria for establishing a Hypertrophic Cardiomyopathy (HOCM) Center of Excellence. These criteria are based on clinical guidelines and expert consensus from leading cardiology societies including the European Society of Cardiology (ESC), the American College of Cardiology (ACC), and major HCM referral programs.<\/div>\n
<\/div>\n
Definition<\/div>\n
<\/div>\n
A Hypertrophic Cardiomyopathy (HOCM) Center of Excellence is a multidisciplinary center designed to provide comprehensive evaluation, genetic counseling, advanced imaging, risk stratification, and personalized management for patients and families affected by hypertrophic cardiomyopathy.<\/div>\n
<\/div>\n
Core Criteria<\/div>\n
<\/div>\n
A. Multidisciplinary HCM Team<\/div>\n
\u2022 Cardiologists specialized in HCM<\/span><\/div>\n
\u2022 Cardiac imaging experts (echocardiography and MRI)<\/span><\/div>\n
\u2022 Geneticists and genetic counselors<\/span><\/div>\n
\u2022 Electrophysiologists<\/span><\/div>\n
\u2022 Cardiac surgeons with experience in septal myectomy<\/span><\/div>\n
\u2022 Nurses and allied health staff trained in inherited cardiac conditions<\/span><\/div>\n
<\/div>\n
B. Advanced Diagnostic Capabilities<\/div>\n
\u2022 Echocardiography with strain imaging<\/span><\/div>\n
\u2022 Cardiac magnetic resonance imaging (MRI)<\/span><\/div>\n
\u2022 Exercise stress testing<\/span><\/div>\n
\u2022 Holter monitoring and inpatient telemetry<\/span><\/div>\n
\u2022 Comprehensive genetic testing and family screening programs<\/span><\/div>\n
<\/div>\n
C. Comprehensive Risk Stratification<\/div>\n
\u2022 Use of ESC HCM risk score for sudden cardiac death (SCD)<\/span><\/div>\n
\u2022 Evaluation for ICD therapy<\/span><\/div>\n
\u2022 Assessment of apical aneurysm, LVOT obstruction, or mid-ventricular gradients<\/span><\/div>\n
<\/div>\n
D. Specialized Treatment Pathways<\/div>\n
\u2022 Medical therapy optimization (e.g., beta-blockers, calcium channel blockers, disopyramide)<\/span><\/div>\n
\u2022 Septal reduction therapy:<\/span><\/div>\n
\u2022 Surgical septal myectomy<\/span><\/div>\n
\u2022 Alcohol septal ablation<\/span><\/div>\n
\u2022 ICD implantation for SCD prevention<\/span><\/div>\n
\u2022 Management strategies for non-obstructive and restrictive HCM variants<\/span><\/div>\n
<\/div>\n
E. Family and Genetic Services<\/div>\n
\u2022 Cascade screening of first-degree relatives<\/span><\/div>\n
\u2022 Genetic counseling and follow-up<\/span><\/div>\n
\u2022 Psychosocial support for patients and families<\/span><\/div>\n
<\/div>\n
F. Long-Term Follow-Up and Registry Participation<\/div>\n
\u2022 Enrollment in HCM registries for outcome tracking<\/span><\/div>\n
\u2022 Structured adolescent-to-adult transition care<\/span><\/div>\n
\u2022 Ongoing follow-up with periodic imaging and rhythm monitoring<\/span><\/div>\n
\u2022 Remote surveillance when appropriate<\/span><\/div>\n
<\/div>\n
G. Research and Innovation<\/div>\n
\u2022 Participation in multicenter HCM clinical trials<\/span><\/div>\n
\u2022 Contribution to genotype-phenotype correlation studies<\/span><\/div>\n
\u2022 Research on risk stratification, new therapies, and patient-reported outcomes<\/span><\/div>\n
<\/div>\n
References<\/div>\n
\u2022 ESC Guidelines on Hypertrophic Cardiomyopathy:<\/span><\/div>\n
https:\/\/www.escardio.org\/Guidelines\/Clinical-Practice-Guidelines\/Hypertrophic-Cardiomyopathy<\/div>\n
\u2022 ACC Expert Consensus on HCM:<\/span><\/div>\n
https:\/\/www.acc.org\/guidelines\/hypertrophic-cardiomyopathy<\/div>\n
\u2022 Johns Hopkins HCM Center of Excellence:<\/span><\/div>\n
https:\/\/www.hopkinsmedicine.org\/heart_vascular_institute\/clinical_services\/centers_excellence\/hcm_center<\/div>\n
\u2022 Mayo Clinic HCM Program:<\/span><\/div>\n
https:\/\/www.mayoclinic.org\/diseases-conditions\/hypertrophic-cardiomyopathy\/care-at-mayo-clinic\/mac-20350230<\/div>\n","protected":false},"excerpt":{"rendered":"

Integrated Criteria for Cardiology Centers of Excellence Developed from key international cardiology guidelines and expert consensus. Source:\u00a0 Integrated Criteria for Cardiology Centers of Excellence In reference to these standards, please find below a concise summary of the internationally recognized criteria for establishing and accrediting Centers of Excellence in cardiology. This framework was developed from key […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8073","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8073","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8073"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8073\/revisions"}],"predecessor-version":[{"id":8074,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8073\/revisions\/8074"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8073"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8073"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8073"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}